$ALMSALUMIS INC.

Active trials

• phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasiscompletedn=912
• phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001completedn=862
• phase2Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosusactive not recruitingn=408
• phase3Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasisactive not recruitingn=1,680
• phase2Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasisactive not recruitingn=165
• phase1An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005completedn=135
• phase1An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001completedn=52
• phase1An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Functioncompletedn=16